Proteogenomics - samples
Ontology highlight
ABSTRACT:
PROVIDER: EGAD00001004875 | EGA |
REPOSITORIES: EGA
Publications
Genomic hallmarks of localized, non-indolent prostate cancer.
Fraser Michael M Sabelnykova Veronica Y VY Yamaguchi Takafumi N TN Heisler Lawrence E LE Livingstone Julie J Huang Vincent V Shiah Yu-Jia YJ Yousif Fouad F Lin Xihui X Masella Andre P AP Fox Natalie S NS Xie Michael M Prokopec Stephenie D SD Berlin Alejandro A Lalonde Emilie E Ahmed Musaddeque M Trudel Dominique D Luo Xuemei X Beck Timothy A TA Meng Alice A Zhang Junyan J D'Costa Alister A Denroche Robert E RE Kong Haiying H Espiritu Shadrielle Melijah G SM Chua Melvin L K ML Wong Ada A Chong Taryne T Sam Michelle M Johns Jeremy J Timms Lee L Buchner Nicholas B NB Orain Michèle M Picard Valérie V Hovington Helène H Murison Alexander A Kron Ken K Harding Nicholas J NJ P'ng Christine C Houlahan Kathleen E KE Chu Kenneth C KC Lo Bryan B Nguyen Francis F Li Constance H CH Sun Ren X RX de Borja Richard R Cooper Christopher I CI Hopkins Julia F JF Govind Shaylan K SK Fung Clement C Waggott Daryl D Green Jeffrey J Haider Syed S Chan-Seng-Yue Michelle A MA Jung Esther E Wang Zhiyuan Z Bergeron Alain A Dal Pra Alan A Lacombe Louis L Collins Colin C CC Sahinalp Cenk C Lupien Mathieu M Fleshner Neil E NE He Housheng H HH Fradet Yves Y Tetu Bernard B van der Kwast Theodorus T McPherson John D JD Bristow Robert G RG Boutros Paul C PC
Nature 20170109 7637
Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastat ...[more]
Similar Datasets
Project description:Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment options for advanced stages. This proteogenomics study aims to integrate multi-omics approaches, including proteomics, genomics, and transcriptomics, to elucidate the molecular mechanisms underlying lung cancer progression and treatment resistance. By leveraging cutting-edge technologies, this study seeks to identify novel biomarkers and therapeutic targets, enabling personalized medicine strategies to improve patient outcomes. The integration of proteogenomic data will provide a comprehensive understanding of tumor biology, revealing critical pathways and interactions that drive tumorigenesis and immune evasion.
2024-12-02 | GSE283245 | GEO
Project description:The Proteogenomic Landscape of Curable Prostate Cancer [microarray]
| PRJNA419650 | ENA
Project description:This study uses advanced proteogenomic approaches in a non-model organism to elucidate cardioprotective mechanisms used during mammalian hibernation. Mammalian hibernation is characterized by dramatic reductions in body temperature, heart rate, metabolism and oxygen consumption. These changes pose significant challenges to the physiology of hibernators, especially for the heart, which maintains function throughout extreme conditions resembling ischemia and reperfusion. To identify novel cardioadaptive strategies we merged large-scale RNA-seq data with large-scale iTRAQ-based proteomic data in heart tissue from thirteen-lined ground squirrels (Ictidomys tridecemlineatus) throughout the circannual cycle. Protein identification and data analysis were run through Galaxy-P, a new multi-omic data analysis platform enabling effective integration of RNA-seq and MS/MS proteomic data. Galaxy-P uses flexible, modular workflows that combine customized sequence database searching and iTRAQ quantification to identify novel ground squirrel-specific protein sequences and provide insight into molecular mechanisms of hibernation. This study allowed for the quantification of 2007 identified cardiac proteins, including over 350 peptide sequences derived from previously uncharacterized protein products. Identification of these peptides allows for improved genomic annotation of this non-model organism, as well as identification of potential splice variants, mutations, or genome re-organization that provide insights into novel cardioprotective mechanisms used during hibernation.
2015-11-03 | PXD002457 | Pride
Project description:Never-smoker lung adenocarcinoma (NSLA) is prevalent in Asian populations and even more in women. Since epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions are major alterations found in NSLA, studies have focused on NSLA with EGFR and ALK alteration (EA), but not for NSLA without EGFR and ALK alteration (NENA). To reveal the proteogenomic landscape of NENA, we selected 101 NSLA tissues without EGFR and ALK by targeted sequencing of 1597 FFPE samples, and performed multiomics analyses including whole genome, transcriptome, methylation EPIC array, total proteome, and phosphoproteome. Genome analysis revealed that TP53 (25%), KRAS (22%), ROS1 fusion (13%), SETD2 (11%), and ERRB2 (9%) were the most frequently mutated genes in NENA. Proteogenomic impact analysis found that STK11 and ERBB2 somatic mutations had more profound effects on cancer-associated genes in NENA. From DNA copy number alteration analysis, we identified 22 prognostic proteins whose expression was controlled through transcriptome from copy number alterations Intriguingly, from gene set enrichment analysis, estrogen signaling emerged as the key pathway activated in NENA compared with EA. Evidence from multiomics analysis including copy number gains in chromosomes 14 and 21, STK11 mutation, and DNA hypomethylation of LLGL2 and ST14, also supported the increased estrogen signaling. Finally, the saracatinib, an Src inhibitor, was suggested as a potential drug for targeting activated estrogen signaling in NENA. Taken together, the proteogenomic landscape for NENA from this study will enhance our understanding of the etiology of NSLA.
2024-03-12 | PXD033360 | Pride
Project description:In the current work, we present the first proteogenomic dataset of GBM clinical samples to date. We have assembled a cohort of 87 GBM patients of varying survival rates and performed MS-based proteomics analysis as well as RNA-seq in order to identify the molecular differences associated with survival and examine the contribution of each layer to GBM landscape. We show that each layer alone only partially reflects patient survival, but RNA-protein integration identifies clear patterns of layer-specific and layer-common processes specifically contributing to either short-term or long-term survival of patients. Furthermore, we compare our data to published single-cell RNA-seq of GBM tumors and evaluate the RNA-protein variability within single-cell based tumor subpopulations. We found that while all signatures of the four subpopulations tend to have high RNA-protein correlation, each signature is associated differently with survival. Altogether, these results highlight the potential of proteogenomics to further stratify heterogeneity in GBM tumors and identify processes contributing to poorer survival.
2021-04-16 | PXD018024 | Pride
Project description:In order to identify relevant targets for cancer immunotherapy in breast cancer, we characterized the immunopeptidome of 26 primary breast cancer samples with a proteogenomic approach relying on RNA-seq and mass spectrometry (MS). We were able to describe the landscape of MHC-I associated peptides presented by breast cancer tumors. Furthermore, bioinformatic analysis allowed us to identify tumor-specific and tumor associated antigens, which can be used for the development of anti-cancer vaccines or as targets for engineered T-cells.
2023-06-01 | GSE206838 | GEO
Project description:RNA-seq access dataset for epigenomics landscape of colorectal cancer
| PRJNA562898 | ENA
Project description:Proteogenomics approaches often struggle with the distinction between right and false peptide-to-spectrum matches as the database size enlarges. However, features extracted from tandem mass spectrometry intensity predictors can enhance the peptide identification rate and can provide extra confidence for spectral matching in a proteogenomic context. To that end, features from the spectral intensity pattern predictors MS2PIP and Prosit were combined with the canonical scores from MaxQuant in the Percolator post-processing tool for protein databases constructed from RNA-seq and ribosome profiling analyses. The presented results provide evidence that this approach enhances the peptide identification power in a proteogenomic setting and in the meantime they lead to the validation of new proteoforms with elevated stringency. In this online repository, we submitted the conventional proteomic search results with MaxQuant against the custom nanopore RNA-seq-based search space. All other results can be found in the supplemental materials of the manuscript, in SRA (sequencing data) or under ProteomeXChange Project PXD011353 (as this is original data from a previuos paper).
2021-03-26 | PXD022280 | Pride
Project description:Therapeutic approaches to treat melanoma include small molecule drugs that target activating protein mutations in pro-growth signaling pathways like the MAPK pathway. While beneficial to the approximately 50% of patients with activating BRAFV600 mutation, mono- and combination therapy with MAPK inhibitors is ultimately associated with acquired resistance. To better characterize the mechanisms of MAPK inhibitor resistance in melanoma, we utilize patient-derived xenografts and apply proteogenomic approaches leveraging genomic, transcriptomic, and proteomic technologies that permit the identification of resistance-specific alterations and therapeutic vulnerabilities. A specific challenge for proteogenomic applications comes at the level of data curation to enable multi-omics data integration. Here, we present a proteogenomic approach that uses custom curated databases to identify unique resistance-specific alternations in melanoma PDX models of acquired MAPK inhibitor resistance. We demonstrate this approach with a NRASQ61L melanoma PDX model from which resistant tumors were developed following treatment with a MEK inhibitor. Our multi-omics strategy addresses current challenges in bioinformatics by leveraging development of custom curated proteogenomics databases derived from individual resistant melanoma that evolves following MEK inhibitor treatment and is scalable to comprehensively characterize acquired MAPK inhibitor resistance across patient-specific models and genomic subtypes of melanoma.
2024-05-10 | GSE266735 | GEO
Project description:Therapeutic approaches to treat melanoma include small molecule drugs that target activating protein mutations in pro-growth signaling pathways like the MAPK pathway. While beneficial to the approximately 50% of patients with activating BRAFV600 mutation, mono- and combination therapy with MAPK inhibitors is ultimately associated with acquired resistance. To better characterize the mechanisms of MAPK inhibitor resistance in melanoma, we utilize patient-derived xenografts and apply proteogenomic approaches leveraging genomic, transcriptomic, and proteomic technologies that permit the identification of resistance-specific alterations and therapeutic vulnerabilities. A specific challenge for proteogenomic applications comes at the level of data curation to enable multi-omics data integration. Here, we present a proteogenomic approach that uses custom curated databases to identify unique resistance-specific alternations in melanoma PDX models of acquired MAPK inhibitor resistance. We demonstrate this approach with a NRASQ61L melanoma PDX model from which resistant tumors were developed following treatment with a MEK inhibitor. Our multi-omics strategy addresses current challenges in bioinformatics by leveraging development of custom curated proteogenomics databases derived from individual resistant melanoma that evolves following MEK inhibitor treatment and is scalable to comprehensively characterize acquired MAPK inhibitor resistance across patient-specific models and genomic subtypes of melanoma.
2024-05-10 | GSE266762 | GEO